Levi & Korsinsky Reminds Cassava Sciences, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of February 10, 2025 – SAVA
Cassava Sciences is facing a class-action lawsuit following the failure of its Alzheimer’s drug candidate, simufilam, in Phase 3 trials. Investors allege securities fraud after the company’s stock plummeted by over 80% in a single day.
7 months ago
3 mins read
